Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-12

AUTHORS

Feng Xie, Gord Blackhouse, Nazila Assasi, Kathryn Gaebel, Diana Robertson, Ron Goeree

ABSTRACT

OBJECTIVE: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year time horizon from the perspective of a publicly-funded health care system. Clinical parameters were derived from the Active Ulcerative Colitis Trials 1 and 2. Costs were obtained through provincial drug benefit plans. ICUR was the main outcome measure and both deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Compared to the strategy A ('usual care') in the base case analysis, the ICURs were CA$358,088/QALY for the strategy B ('5 mg/kg infliximab + adalimumab') and CA$575,540/QALY for the strategy C ('5 mg/kg and 10 mg/kg infliximab + adalimumab'). The results were sensitive to: the remission rates maintained in responders to 'usual care' and to 5 mg/kg infliximab, the rate of remission induced by adalimumab in non-responders to 5 mg/kg infliximab, early surgery rate, and utility values. When the willingness to pay (WTP) was less than CA$150,000/QALY, the probability of 'usual care' being the optimal strategy was 1.0. The probability of strategy B being optimal was 0.5 when the WTP approximated CA$400,000/QALY. CONCLUSIONS: The ICURs of anti-TNF-alpha drugs were not satisfactory in treating patients with moderate-to-severe refractory UC. Future research could be aimed at the long-term clinical benefits of these drugs, especially adalimumab for patients intolerant or unresponsive to infliximab treatment. More... »

PAGES

20

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1478-7547-7-20

DOI

http://dx.doi.org/10.1186/1478-7547-7-20

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013421354

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20003364


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada", 
            "Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Feng", 
        "id": "sg:person.01044642125.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044642125.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada", 
            "Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blackhouse", 
        "givenName": "Gord", 
        "id": "sg:person.0632212475.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632212475.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada", 
            "Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Assasi", 
        "givenName": "Nazila", 
        "id": "sg:person.01144471713.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144471713.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gaebel", 
        "givenName": "Kathryn", 
        "id": "sg:person.01131002675.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131002675.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada", 
            "Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "Diana", 
        "id": "sg:person.0657052007.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657052007.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Programs for Assessment of Technology in Health Research Institute", 
          "id": "https://www.grid.ac/institutes/grid.452761.3", 
          "name": [
            "Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada", 
            "Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goeree", 
        "givenName": "Ron", 
        "id": "sg:person.01052355256.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052355256.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1136/bmj.2.4947.1041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004911330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200212123472418", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007350801"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2006.00603.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011782052", 
          "https://doi.org/10.1111/j.1572-0241.2006.00603.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0300-2977(96)00065-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019550069"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/gut.52.7.998", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019963189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10350-004-6653-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023403912", 
          "https://doi.org/10.1007/s10350-004-6653-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1007/s10350-004-6653-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023403912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.gastro.2006.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029632619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.gastro.2005.03.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029727817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cgh.2006.05.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032351260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-199508000-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032860420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000658-199508000-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032860420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00054725-200105000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037341581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00054725-200105000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037341581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2008.03811.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040519058"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa050516", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042784686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2008.03839.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043473964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/b978-0-7295-3775-9.50016-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047167942"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/sla.0b013e31814539b1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047776214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/sla.0b013e31814539b1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047776214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3748/wjg.v13.i16.2328", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071365712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075313519", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-12", 
    "datePublishedReg": "2009-12-01", 
    "description": "OBJECTIVE: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada.\nMETHODS: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year time horizon from the perspective of a publicly-funded health care system. Clinical parameters were derived from the Active Ulcerative Colitis Trials 1 and 2. Costs were obtained through provincial drug benefit plans. ICUR was the main outcome measure and both deterministic and probabilistic sensitivity analyses were conducted.\nRESULTS: Compared to the strategy A ('usual care') in the base case analysis, the ICURs were CA$358,088/QALY for the strategy B ('5 mg/kg infliximab + adalimumab') and CA$575,540/QALY for the strategy C ('5 mg/kg and 10 mg/kg infliximab + adalimumab'). The results were sensitive to: the remission rates maintained in responders to 'usual care' and to 5 mg/kg infliximab, the rate of remission induced by adalimumab in non-responders to 5 mg/kg infliximab, early surgery rate, and utility values. When the willingness to pay (WTP) was less than CA$150,000/QALY, the probability of 'usual care' being the optimal strategy was 1.0. The probability of strategy B being optimal was 0.5 when the WTP approximated CA$400,000/QALY.\nCONCLUSIONS: The ICURs of anti-TNF-alpha drugs were not satisfactory in treating patients with moderate-to-severe refractory UC. Future research could be aimed at the long-term clinical benefits of these drugs, especially adalimumab for patients intolerant or unresponsive to infliximab treatment.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1478-7547-7-20", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032048", 
        "issn": [
          "1478-7547"
        ], 
        "name": "Cost Effectiveness and Resource Allocation", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis", 
    "pagination": "20", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3fefce825461dd84c0020031f864b1d2ecee805aa68f6a1b7ed630753facf9c5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20003364"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101170476"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1478-7547-7-20"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013421354"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1478-7547-7-20", 
      "https://app.dimensions.ai/details/publication/pub.1013421354"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000511.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1478-7547-7-20"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-7-20'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-7-20'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-7-20'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1478-7547-7-20'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      21 PREDICATES      48 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1478-7547-7-20 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N6105d04b15b04b9b841044df33a5d58f
4 schema:citation sg:pub.10.1007/s10350-004-6653-7
5 sg:pub.10.1111/j.1572-0241.2006.00603.x
6 https://app.dimensions.ai/details/publication/pub.1075313519
7 https://doi.org/10.1007/s10350-004-6653-7
8 https://doi.org/10.1016/b978-0-7295-3775-9.50016-0
9 https://doi.org/10.1016/j.cgh.2006.05.003
10 https://doi.org/10.1016/s0300-2977(96)00065-4
11 https://doi.org/10.1053/j.gastro.2005.03.003
12 https://doi.org/10.1053/j.gastro.2006.11.015
13 https://doi.org/10.1056/nejm200212123472418
14 https://doi.org/10.1056/nejmoa050516
15 https://doi.org/10.1097/00000658-199508000-00003
16 https://doi.org/10.1097/00054725-200105000-00001
17 https://doi.org/10.1097/sla.0b013e31814539b1
18 https://doi.org/10.1111/j.1365-2036.2008.03811.x
19 https://doi.org/10.1111/j.1365-2036.2008.03839.x
20 https://doi.org/10.1136/bmj.2.4947.1041
21 https://doi.org/10.1136/gut.52.7.998
22 https://doi.org/10.3748/wjg.v13.i16.2328
23 schema:datePublished 2009-12
24 schema:datePublishedReg 2009-12-01
25 schema:description OBJECTIVE: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patients (aged 40 years and weighing 80 kg) over a five-year time horizon from the perspective of a publicly-funded health care system. Clinical parameters were derived from the Active Ulcerative Colitis Trials 1 and 2. Costs were obtained through provincial drug benefit plans. ICUR was the main outcome measure and both deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Compared to the strategy A ('usual care') in the base case analysis, the ICURs were CA$358,088/QALY for the strategy B ('5 mg/kg infliximab + adalimumab') and CA$575,540/QALY for the strategy C ('5 mg/kg and 10 mg/kg infliximab + adalimumab'). The results were sensitive to: the remission rates maintained in responders to 'usual care' and to 5 mg/kg infliximab, the rate of remission induced by adalimumab in non-responders to 5 mg/kg infliximab, early surgery rate, and utility values. When the willingness to pay (WTP) was less than CA$150,000/QALY, the probability of 'usual care' being the optimal strategy was 1.0. The probability of strategy B being optimal was 0.5 when the WTP approximated CA$400,000/QALY. CONCLUSIONS: The ICURs of anti-TNF-alpha drugs were not satisfactory in treating patients with moderate-to-severe refractory UC. Future research could be aimed at the long-term clinical benefits of these drugs, especially adalimumab for patients intolerant or unresponsive to infliximab treatment.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N7d67c27366dc4bce8d0d92d4aea6f674
30 Ne9c06e68933e4146a3e1f48c6c112c2d
31 sg:journal.1032048
32 schema:name Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
33 schema:pagination 20
34 schema:productId N298dd2a5c84349b885cb9a9d4fdae12e
35 N364f9ec62fc945b29a9a494472f67224
36 N58410ac5204d46c8a02714bfb056016e
37 N7e6e420933464ad2838c28878223dc26
38 Nb34a5ec62a6340b88ddfafa9ea91af07
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013421354
40 https://doi.org/10.1186/1478-7547-7-20
41 schema:sdDatePublished 2019-04-10T20:46
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher N91d39e9a8a8941fdade18d4e56a1b574
44 schema:url http://link.springer.com/10.1186%2F1478-7547-7-20
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N298dd2a5c84349b885cb9a9d4fdae12e schema:name nlm_unique_id
49 schema:value 101170476
50 rdf:type schema:PropertyValue
51 N2c73017835924d5e967a5715052a4864 rdf:first sg:person.01052355256.25
52 rdf:rest rdf:nil
53 N32273b98adac409db5690d7cd067d8de rdf:first sg:person.01144471713.97
54 rdf:rest Nb5c034b01b2c4034b4a9a00bdbace5f9
55 N364f9ec62fc945b29a9a494472f67224 schema:name doi
56 schema:value 10.1186/1478-7547-7-20
57 rdf:type schema:PropertyValue
58 N58410ac5204d46c8a02714bfb056016e schema:name dimensions_id
59 schema:value pub.1013421354
60 rdf:type schema:PropertyValue
61 N5b49575aea044362baee8139e5cea064 rdf:first sg:person.0657052007.41
62 rdf:rest N2c73017835924d5e967a5715052a4864
63 N6105d04b15b04b9b841044df33a5d58f rdf:first sg:person.01044642125.66
64 rdf:rest Ncbc735639d9a4898947aefe6d26d6f39
65 N7d67c27366dc4bce8d0d92d4aea6f674 schema:issueNumber 1
66 rdf:type schema:PublicationIssue
67 N7e6e420933464ad2838c28878223dc26 schema:name pubmed_id
68 schema:value 20003364
69 rdf:type schema:PropertyValue
70 N91d39e9a8a8941fdade18d4e56a1b574 schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 Nb34a5ec62a6340b88ddfafa9ea91af07 schema:name readcube_id
73 schema:value 3fefce825461dd84c0020031f864b1d2ecee805aa68f6a1b7ed630753facf9c5
74 rdf:type schema:PropertyValue
75 Nb5c034b01b2c4034b4a9a00bdbace5f9 rdf:first sg:person.01131002675.90
76 rdf:rest N5b49575aea044362baee8139e5cea064
77 Ncbc735639d9a4898947aefe6d26d6f39 rdf:first sg:person.0632212475.32
78 rdf:rest N32273b98adac409db5690d7cd067d8de
79 Ne9c06e68933e4146a3e1f48c6c112c2d schema:volumeNumber 7
80 rdf:type schema:PublicationVolume
81 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
82 schema:name Medical and Health Sciences
83 rdf:type schema:DefinedTerm
84 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
85 schema:name Public Health and Health Services
86 rdf:type schema:DefinedTerm
87 sg:journal.1032048 schema:issn 1478-7547
88 schema:name Cost Effectiveness and Resource Allocation
89 rdf:type schema:Periodical
90 sg:person.01044642125.66 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
91 schema:familyName Xie
92 schema:givenName Feng
93 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044642125.66
94 rdf:type schema:Person
95 sg:person.01052355256.25 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
96 schema:familyName Goeree
97 schema:givenName Ron
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052355256.25
99 rdf:type schema:Person
100 sg:person.01131002675.90 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
101 schema:familyName Gaebel
102 schema:givenName Kathryn
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131002675.90
104 rdf:type schema:Person
105 sg:person.01144471713.97 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
106 schema:familyName Assasi
107 schema:givenName Nazila
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144471713.97
109 rdf:type schema:Person
110 sg:person.0632212475.32 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
111 schema:familyName Blackhouse
112 schema:givenName Gord
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632212475.32
114 rdf:type schema:Person
115 sg:person.0657052007.41 schema:affiliation https://www.grid.ac/institutes/grid.452761.3
116 schema:familyName Robertson
117 schema:givenName Diana
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657052007.41
119 rdf:type schema:Person
120 sg:pub.10.1007/s10350-004-6653-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023403912
121 https://doi.org/10.1007/s10350-004-6653-7
122 rdf:type schema:CreativeWork
123 sg:pub.10.1111/j.1572-0241.2006.00603.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011782052
124 https://doi.org/10.1111/j.1572-0241.2006.00603.x
125 rdf:type schema:CreativeWork
126 https://app.dimensions.ai/details/publication/pub.1075313519 schema:CreativeWork
127 https://doi.org/10.1007/s10350-004-6653-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023403912
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1016/b978-0-7295-3775-9.50016-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047167942
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1016/j.cgh.2006.05.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032351260
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1016/s0300-2977(96)00065-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019550069
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1053/j.gastro.2005.03.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029727817
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1053/j.gastro.2006.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029632619
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1056/nejm200212123472418 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007350801
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1056/nejmoa050516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042784686
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1097/00000658-199508000-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032860420
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1097/00054725-200105000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037341581
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1097/sla.0b013e31814539b1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047776214
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1111/j.1365-2036.2008.03811.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040519058
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1111/j.1365-2036.2008.03839.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043473964
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1136/bmj.2.4947.1041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004911330
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1136/gut.52.7.998 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019963189
156 rdf:type schema:CreativeWork
157 https://doi.org/10.3748/wjg.v13.i16.2328 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071365712
158 rdf:type schema:CreativeWork
159 https://www.grid.ac/institutes/grid.452761.3 schema:alternateName Programs for Assessment of Technology in Health Research Institute
160 schema:name Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
161 Programs for Assessment of Technology in Health (PATH) Research Institute, St. Joseph's Healthcare, Hamilton, Ontario, Canada
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...